TTI-237

Phase 1Terminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neoplasms

Conditions

Neoplasms

Trial Timeline

May 1, 2005 → —

NCT ID

NCT00195247

About TTI-237

TTI-237 is a phase 1 stage product being developed by Pfizer for Neoplasms. The current trial status is terminated. This product is registered under clinical trial identifier NCT00195247. Target conditions include Neoplasms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00195325	Phase 1	Terminated	Aug 1, 2005	—	Tumors
NCT00195247	Phase 1	Terminated	May 1, 2005	—	Neoplasms

Competing Products

20 competing products in Neoplasms

See all competitors

Product	Company	Stage	Hype Score
AB0024	Gilead Sciences	Phase 1	32
852A	Pfizer	Phase 1	32
Pemetrexed	Eli Lilly	Phase 2	52
IMC-3C5	Eli Lilly	Phase 1	33
LY3295668	Eli Lilly	Phase 1/2	41
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	41
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	77
LY2784544	Eli Lilly	Phase 1	33
enzastaurin	Eli Lilly	Phase 2	52
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	33
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	77
120 mg LY2784544	Eli Lilly	Phase 2	52
LY4337713	Eli Lilly	Phase 1	33
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	41
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	77
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	25
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	25
GEMZAR + ALIMTA	Eli Lilly	Phase 3	77
Trastuzumab Deruxtecan + Paclitaxel + Trastuzumab + Pertuzumab + Doxorubicin + cyclophosphamide	Daiichi Sankyo	Phase 3	77

Other Products from Pfizer